stockrow
Friday 6 November 2026
Export CASIF’s income statement to Excel — free account
CASI Pharmaceuticals Inc.
CASIF Healthcare Biotechnology
CASI Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.7 million, down 27.4% from fiscal 2024.
- Revenue
- −45.9%
- EPS
- +35.8%
- Free cash flow
- −23,251.7%
- Total debt
- +6.97%
Quarter to December 2025, against a year earlier
0.11
0.01
+10.00%
Follow CASIF
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 5 | 4 | 4 | 3 | 4 |
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | (1.95) | (2.65) | (5.27) | (9.00) | (11.14) | (19.57) | (47.08) |
P/S ratio |
— | — | — | 71.35 | 21.52 | 3.61 | 0.58 | 2.85 | 1.52 | 0.76 |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | (13.50) | (12.09) | (12.33) | (19.21) | (26.65) | (47.01) | (116.19) |
Beneish M-Score |
— | — | — | — | (1.08) | (1.75) | (3.65) | (3.79) | (2.51) | (8.73) |
P/Operating CF |
— | — | — | (61.54) | (40.57) | (14.25) | (29.79) | (114.42) | (1.49) | (0.76) |
P/B ratio |
— | — | — | 4.06 | 4.00 | 1.29 | 0.56 | 3.99 | 23.45 | 0.00 |
Price to Tangible BV |
— | — | — | 5.00 | 4.77 | 1.51 | 0.58 | 4.32 | 26.91 | 0.00 |
EV/Sales |
— | — | — | 58.83 | 17.25 | 2.11 | (0.50) | 2.61 | 2.27 | 2.54 |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | 0.00 | 0.69 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | (10.52) | (10.09) | (2.37) | 1.03 | (2.18) | (1.19) | (0.76) |
EV/FCF |
— | — | — | (10.33) | (10.58) | (1.83) | 0.82 | (1.90) | (1.15) | (0.75) |
Quick Ratio |
20.59 | 8.59 | 21.98 | 6.99 | 8.90 | 4.43 | 3.78 | 2.45 | 0.86 | 0.20 |
Current Ratio |
20.86 | 8.66 | 23.90 | 8.14 | 9.28 | 4.70 | 4.32 | 3.55 | 1.09 | 0.27 |
Net Debt/EBITDA |
2.74 | 3.95 | 3.28 | 1.16 | 1.27 | 1.14 | 1.62 | 0.56 | (0.06) | (0.43) |
Debt/Assets |
5.38% | 3.32% | 1.32% | 2.14% | 1.40% | 2.37% | 0.00% | 25.10% | 34.25% | 91.36% |
Debt/Equity |
0.07 | 0.04 | 0.01 | 0.03 | 0.02 | 0.04 | 0.00 | 0.78 | 9.93 | (0.63) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.04 | 0.13 | 0.23 | 0.37 | 0.40 | 0.44 | 0.52 |
Operating CF/Net income |
0.64 | 0.59 | 1.04 | 0.50 | 0.54 | 0.73 | 0.51 | 0.74 | 0.74 | 0.43 |
Capex/Depreciation |
(0.97) | (7.93) | (0.68) | (0.20) | 0.61 | (4.92) | (2.26) | (0.60) | 0.11 | (0.02) |
Interest Coverage |
(360.94) | (671.96) | (564.13) | (44.22) | (60.95) | (129.33) | — | (1,672.00) | (45.02) | (51.01) |
| (128.65%) | (36.31%) | (37.12%) | (50.46%) | (62.49%) | (44.15%) | (63.55%) | (78.44%) | (301.80%) | 271.28% | |
| (56.37%) | (29.58%) | (34.66%) | (42.61%) | (41.92%) | (27.56%) | (34.98%) | (31.44%) | (60.89%) | (121.17%) | |
ROIC |
0.00% | 0.00% | (65.75%) | (140.09%) | (194.53%) | (66.19%) | 0.00% | (127.53%) | (591.25%) | 0.00% |
Return on Tangible Assets |
(35.86%) | (27.06%) | (30.37%) | (79.70%) | (70.89%) | (59.60%) | (60.09%) | (51.99%) | (357.15%) | 164.33% |
Average Days of Receivables |
— | — | — | 114.24 | 111.98 | 118.61 | 109.85 | 109.22 | 196.27 | 72.11 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 226.10% | 75.75% | 47.81% | 37.11% | 29.11% | 31.25% | 30.46% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 736.84% | 181.47% | 127.31% | 87.63% | 123.49% | 145.23% | 225.06% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.17 | 0.13 | 0.10 | 0.09 | 0.01 | 0.02 | 0.00 | 0.01 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 176.95% | 51.65% | 25.76% | 16.26% | 21.30% | 4.58% | 14.42% |
Graham Net Nets |
— | — | — | 0.12 | 0.09 | 0.08 | 0.87 | 0.09 | (0.28) | (3.14) |
Graham Number |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.06 |
Earnings Yield |
— | — | — | (15.53%) | (14.92%) | (33.75%) | (161.96%) | (27.98%) | (89.39%) | (317.82%) |
Free Cash Flow Yield |
— | — | — | (7.98%) | (7.58%) | (31.93%) | (105.19%) | (48.19%) | (129.67%) | (447.18%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.43 | 1.37 | 2.22 | 3.16 | 2.54 | 1.86 | 1.12 |
Operating CF per Share |
(1.08) | (1.04) | (3.37) | (2.42) | (2.34) | (1.97) | (1.55) | (1.49) | (1.91) | (1.12) |
Capex per Share |
(0.01) | (0.15) | (0.13) | (0.04) | 0.11 | (0.66) | (0.40) | (0.17) | 0.02 | 0.00 |
Free Cash Flow per Share |
(1.09) | (1.19) | (3.51) | (2.47) | (2.23) | (2.63) | (1.95) | (1.66) | (1.89) | (1.12) |
Cash per Share |
4.85 | 7.07 | 10.04 | 5.65 | 6.01 | 3.57 | 3.76 | 2.30 | 1.05 | 0.30 |
Shareholders Equity per Share |
3.72 | 6.27 | 12.92 | 7.61 | 7.38 | 6.21 | 3.27 | 1.81 | 0.12 | (2.01) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.72 | 6.27 | 12.92 | 7.61 | 7.38 | 6.21 | 3.27 | 1.81 | 0.12 | (2.01) |
Free Cash Flow |
(6.09) | (7.34) | (29.71) | (23.67) | (24.68) | (35.78) | (26.56) | (22.21) | (28.96) | (20.78) |
Working Capital |
26.13 | 38.75 | 88.69 | 56.78 | 66.05 | 48.78 | 56.42 | 42.62 | 3.12 | (36.21) |
Capital Expenditures |
(0.06) | (0.93) | (1.13) | (0.43) | 1.20 | (8.93) | (5.47) | (2.24) | 0.26 | (0.03) |
Net Current Asset Value |
20.52 | 37.25 | 88.62 | 35.09 | 27.83 | 8.17 | 21.76 | 8.24 | (12.25) | (49.47) |
EV/EBIT |
— | — | — | 0.00 | 0.00 | 0.00 | 0.64 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.10 | (0.08) | 0.30 | 0.13 | 0.07 | (0.01) | 0.00 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.29 | 0.11 | 0.95 | 2.19 | 0.95 | 0.14 | 0.20 | 0.40 | 0.30 | 0.18 |
Cash ROIC |
(12.33%) | (8.78%) | (15.15%) | (18.29%) | (16.49%) | (26.24%) | (27.69%) | (30.08%) | (79.73%) | 252.93% |
Accounts Receivable Turnover |
— | — | — | 6.27 | 5.10 | 4.18 | 3.79 | 2.93 | 2.24 | 2.13 |
Accounts Payable Turnover |
0.07 | 0.07 | 1.09 | 1.29 | 2.27 | 4.58 | 5.74 | 3.58 | 4.86 | 5.62 |
Inventory Turnover |
0.00 | 0.00 | 0.69 | 1.63 | 3.22 | 7.70 | 3.93 | 1.26 | 1.65 | 3.11 |
Average Days of Payables |
5,843.29 | 6,468.99 | 211.45 | 474.27 | 125.15 | 64.62 | 75.85 | 117.15 | 57.15 | 36.55 |
Days of Inventory on Hand |
0.00 | 0.00 | 61.82 | 421.30 | 52.06 | 55.43 | 141.55 | 419.12 | 110.23 | 54.84 |
Average Receivables |
— | — | — | 0.66 | 2.97 | 7.22 | 11.39 | 11.56 | 12.74 | 9.72 |
Average Payables |
0.97 | 1.58 | 1.53 | 3.04 | 4.19 | 2.74 | 2.76 | 3.86 | 3.58 | 1.89 |
Average Inventory |
— | — | 2.41 | 2.41 | 2.95 | 1.63 | 4.02 | 11.01 | 10.56 | 3.43 |
Average Assets |
16.77 | 36.41 | 79.26 | 108.02 | 115.18 | 133.02 | 117.27 | 85.75 | 64.47 | 39.66 |
Average Common Equity |
7.35 | 29.66 | 74.00 | 91.23 | 77.27 | 83.02 | 64.54 | 34.37 | 13.01 | (17.72) |
Columns are period end dates · fundamentals updated 25 Oct 2026